Jonathan
Gilbert, cannabis industry veteran, and founder and former CEO of
SOL Global Investments Corp. (CSE:SOL) (Frankfurt:9SB)
(OTCQB:SOLCF), whose wholly owned subsidiary, Scythian Biosciences
Inc. (“SBI”), is seeking to list SBI as a new public
company on the Canadian Stock Exchange (“CSE”)
following a successful capital raise and spinout.

Philip
Young, CEO of Exactus said, “We are proud to compliment
Jonathan on his new venture and believe there are many great
benefits from the use of cannabinoids. There is a large gap in the
availability of controlled clinical trial data demonstrating the
health benefits of this amazing plant, and we look forward to
seeing the research that is produced by Jonathan’s efforts as
well as data we intend to develop. Together we will raise the level
of the clinical understanding and generate data meaningful to the
use of CBD and all cannabinoids.”

SBI
will be renamed “Impact Biosciences Corp”
(“Impact”) and will continue to pursue a drug
application for the prevention and treatment of concussions and
traumatic brain injury with its proprietary Cannabinoid combination
drug candidate with the University of Miami. Impact's mission is to
become the first accepted drug regimen for concussive treatment.
Impact has a collaboration with the University of Miami and its
world-renowned neuroscientific team to conduct pre-clinical and
clinical trials of its drug regimen.

Exactus
is a new leader in the industrial hemp CBD industry with a mission
to become the most trusted CBD brand. Exactus is setting the
industry standards on transparency and quality with every product
and will support clinical research that increases the education of
consumers and healthcare providers to help patients suffering from
various chronic illnesses.

Today
the Exactus Inc. ticker symbol for its common stock will revert
back to "EXDI" (OTCQB: EXDI). As a result of the Company's
one-for-eight reverse stock split which became effective March 11,
2019, the Company's common stock had been trading on a post-split
basis under the temporary trading symbol "EXDID" for 20 trading
days.

Recently,
Exactus announced that it placed its first million-dollar product
order from its partner and largest shareholder Ceed2Med. The
availability of the tinctures, gel caps and topical lotions puts
Exactus in a strong position to meet the consumer demand generated
from Hemp Healthy®, the
company’s direct to consumer platform. Coinciding with
the recently announced Exactus One World 200-acre Oregon farm
acquisition, this ensures Exactus the quantity, quality controls
and capabilities sufficient to ensure product availability through
2020.

For information about Exactus, their products and availability,
please call 804-205-5036 or email,ir@exactusinc.com.For more information about Hemp
Healthy®, or to purchase products, visit
www.buyhempcbd.com.

About Exactus:

Exactus, Inc., is
a healthcare
company pursuing
opportunities in two distinct business segments, Hemp
derived, Cannabidiol,
which is more commonly referred to as CBD. Industrial hemp is a
type of cannabis, defined by the federal government as having THC
(tetrahydrocannabinol) content of 0.3 percent or less. That amount
has not been shown to make a person feel "high."THC is the psychoactive compound found
in cannabis.The company is
also developing point of care diagnostics. For more information
about Exactus:www.exactusinc.com.

Investor Notice

Investing in our securities involves a high degree of risk. Before
making an investment decision, you should carefully consider the
risks, uncertainties and forward-looking statements described under
"Risk Factors" in Item 1A of our most recent Form 10-K for the
fiscal year ended December 31, 2018 filed with the Securities and
Exchange Commission (the "SEC") on March 29, 2019 and under the
heading “Risk Factors” in our Current Report on Form
8-K filed with the SEC on January 14, 2019, and in other periodic
and current reports we file with the SEC. If any of these
risks were to occur, our business, financial condition or results
of operations would likely suffer. In that event, the value of our
securities could decline, and you could lose part or all of your
investment. The risks and uncertainties we describe are not the
only ones facing us. Additional risks not presently known to us or
that we currently deem immaterial may also impair our business
operations. In addition, our past financial performance may not be
a reliable indicator of future performance, and historical trends
should not be used to anticipate results in the future. See "Safe
Harbor" below.

Safe Harbor - Forward Looking Statements

The information provided in this press release may include
forward-looking statements relating to future events or the future
financial performance of the Company. Because such statements are
subject to risks and uncertainties, actual results may differ
materially from those expressed or implied by such forward-looking
statements. Words such as "anticipates," "plans," "expects,"
"intends," "will," "potential," "hope" and similar expressions are
intended to identify forward-looking statements. These
forward-looking statements are based upon current expectations of
the Company and involve assumptions that may never materialize or
may prove to be incorrect. Actual results and the timing of events
could differ materially from those anticipated in such
forward-looking statements as a result of various risks and
uncertainties. Detailed information regarding factors that may
cause actual results to differ materially from the results
expressed or implied by statements in this press release relating
to the Company may be found in the Company's periodic and current
filings with the SEC, including the factors described in the
sections entitled "Risk Factors", copies of which may be obtained
from the SEC's website at www.sec.gov. The Company does not
undertake any obligation to update forward-looking statements
contained in this press release.